Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11103172rdf:typepubmed:Citationlld:pubmed
pubmed-article:11103172lifeskim:mentionsumls-concept:C0008059lld:lifeskim
pubmed-article:11103172lifeskim:mentionsumls-concept:C0031327lld:lifeskim
pubmed-article:11103172lifeskim:mentionsumls-concept:C0592511lld:lifeskim
pubmed-article:11103172lifeskim:mentionsumls-concept:C0073571lld:lifeskim
pubmed-article:11103172lifeskim:mentionsumls-concept:C0574032lld:lifeskim
pubmed-article:11103172lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:11103172lifeskim:mentionsumls-concept:C0443252lld:lifeskim
pubmed-article:11103172pubmed:issue3lld:pubmed
pubmed-article:11103172pubmed:dateCreated2000-12-7lld:pubmed
pubmed-article:11103172pubmed:abstractTextThe clinical efficacy and pharmacokinetics of long-term epidural ropivacaine infusion were investigated in 18 postoperative children aged between 0.3 and 7.3 yr. A lumbar or thoracic epidural catheter was inserted after the anaesthetic induction. Sixty minutes following a bolus dose of ropivacaine 1 mg kg-1, 0.2% ropivacaine was infused at a fixed rate of 0.4 mg kg-1 h-1 for a mean of 61.3 h (range 36-96 h). Clinical evaluation comprised hourly recording of pain, sedation, motor block, nausea/vomiting, pruritus-scores, SpO2, pulse and respiratory rates, and recording of non-invasive arterial pressure every 4 h. Total and free plasma concentrations were measured by high-performance liquid chromatography at 0, 1, 6, 12, 24, 36, 48, 72 and 96 h. Analgesia was of high quality and side effects were minor. No clinical signs of local anaesthetic toxicity were seen. Total (100-3189 micrograms litre-1) and free (10-56 micrograms litre-1) ropivacaine concentrations were within the range reported to be 'safe' in previous studies in adults. Mean (95% CI) volume of distribution was 3.1 litre kg-1 (2.1-4.2 litre kg-1), total clearance was 8.5 ml kg-1 min-1 (5.8-11.1 ml kg-1 min-1), free clearance was 220 ml kg-1 min-1 (170-270 ml kg-1 min-1) and elimination half-life was 4.9 h (3.0-6.7 h).lld:pubmed
pubmed-article:11103172pubmed:languageenglld:pubmed
pubmed-article:11103172pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11103172pubmed:citationSubsetIMlld:pubmed
pubmed-article:11103172pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11103172pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11103172pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11103172pubmed:statusMEDLINElld:pubmed
pubmed-article:11103172pubmed:monthSeplld:pubmed
pubmed-article:11103172pubmed:issn0007-0912lld:pubmed
pubmed-article:11103172pubmed:authorpubmed-author:IlettK FKFlld:pubmed
pubmed-article:11103172pubmed:authorpubmed-author:HackettL PLPlld:pubmed
pubmed-article:11103172pubmed:authorpubmed-author:ReidCClld:pubmed
pubmed-article:11103172pubmed:authorpubmed-author:TANY TYTlld:pubmed
pubmed-article:11103172pubmed:authorpubmed-author:HansenT GTGlld:pubmed
pubmed-article:11103172pubmed:authorpubmed-author:BergesioRRlld:pubmed
pubmed-article:11103172pubmed:issnTypePrintlld:pubmed
pubmed-article:11103172pubmed:volume85lld:pubmed
pubmed-article:11103172pubmed:ownerNLMlld:pubmed
pubmed-article:11103172pubmed:authorsCompleteYlld:pubmed
pubmed-article:11103172pubmed:pagination347-53lld:pubmed
pubmed-article:11103172pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:11103172pubmed:meshHeadingpubmed-meshheading:11103172...lld:pubmed
pubmed-article:11103172pubmed:meshHeadingpubmed-meshheading:11103172...lld:pubmed
pubmed-article:11103172pubmed:meshHeadingpubmed-meshheading:11103172...lld:pubmed
pubmed-article:11103172pubmed:meshHeadingpubmed-meshheading:11103172...lld:pubmed
pubmed-article:11103172pubmed:meshHeadingpubmed-meshheading:11103172...lld:pubmed
pubmed-article:11103172pubmed:meshHeadingpubmed-meshheading:11103172...lld:pubmed
pubmed-article:11103172pubmed:meshHeadingpubmed-meshheading:11103172...lld:pubmed
pubmed-article:11103172pubmed:meshHeadingpubmed-meshheading:11103172...lld:pubmed
pubmed-article:11103172pubmed:meshHeadingpubmed-meshheading:11103172...lld:pubmed
pubmed-article:11103172pubmed:meshHeadingpubmed-meshheading:11103172...lld:pubmed
pubmed-article:11103172pubmed:meshHeadingpubmed-meshheading:11103172...lld:pubmed
pubmed-article:11103172pubmed:meshHeadingpubmed-meshheading:11103172...lld:pubmed
pubmed-article:11103172pubmed:meshHeadingpubmed-meshheading:11103172...lld:pubmed
pubmed-article:11103172pubmed:meshHeadingpubmed-meshheading:11103172...lld:pubmed
pubmed-article:11103172pubmed:meshHeadingpubmed-meshheading:11103172...lld:pubmed
pubmed-article:11103172pubmed:year2000lld:pubmed
pubmed-article:11103172pubmed:articleTitlePharmacokinetics and clinical efficacy of long-term epidural ropivacaine infusion in children.lld:pubmed
pubmed-article:11103172pubmed:affiliationDepartment of Paediatric Anaesthesia, Princess Margaret Hospital for Children, Subiaco, Australia.lld:pubmed
pubmed-article:11103172pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11103172pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:11103172pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed